Peripheral effects of three novel non-peptide tachykinin NK1 receptor antagonists in the anaesthetized rat

European Journal of Pharmacology

Volumn 318, Issue 2-3, 1996, Pages 377-385

  Cellier, Eric ^a   Fayolle, Christine ^a   Hipskind, Philip A ^b   Iyengar, Smriti ^b   Couture, Réjean ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Blood pressure; Salivation; Substance P; Tachykinin NK1 receptor; Tachykinin receptor antagonist

Indexed keywords

CARBACHOL; NEUROKININ 1 RECEPTOR; NEUROKININ A [4-10][8 BETA ALANINE]; SENKTIDE; TACHYKININ RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; ENANTIOMER; INTRAVENOUS DRUG ADMINISTRATION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SALIVATION;

EID: 0030607655     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(96)00808-4     Document Type: Article

References (34)

1. 8]physalaemin to rat submaxillary gland substance P receptor, Mol. Pharmacol. 27, 38.
2. Buck, S. and E. Burcher, 1985, The rat submaxillary gland contains predominantly P-type tachykinin binding sites, Peptides 6, 1079.
3. Cellier, E., P. Picard, L. Barbot and R. Couture, 1995, The non peptide SR142801 behaves as a full agonist in the rat central nervous system, in: International Symposium: Tachykinins '95 - From Basic Science to Clinical Applications, Florence (Italy), October 16-18, Abstract, p. 91.
4. Clerc, F.F., F. Foucault, L. Ridoux-Silly and V. Fardin, 1992, Affinity and stability of some substance P agonists in rat and guinea-pig: a comparative study in central and peripheral tissues, Neuropeptides 22, 14.
5. Couture, R., O. Laneuville, C. Guimond, G. Drapeau and D. Regoli, 1989, Characterization of the peripheral action of neurokinins and neurokinin receptor selective agonists on the rat cardiovascular system, Naunyn-Schmiedeberg's Arch. Pharmacol. 340, 547.
6. 1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B, Br. J. Pharmacol. 114, 1310.
7. D'Orléans-Juste, P., S. Dion, J. Mizrahi and D. Regoli, 1985, Effects of peptides and non-peptides on isolated arterial smooth muscles: role of endothelium, Eur. J. Pharmacol. 114, 9.
8. 1 receptor antagonist, Eur. J. Pharmacol. 250, 403.
9. Garret, C., A. Carruette, V. Fardin, S. Moussaoui, J.F. Peyronel, J.C. Blanchard and P.M. Laduron, 1991, Pharmacological properties of a potent and selective nonpeptide substance P antagonist, Proc. Natl. Acad. Sci. USA 88, 10208.
10. Gitter, B.D., R.F. Bruns, J.J. Howbert, D.C. Waters, P.G. Threlkeld, L.M. Cox, J.A. Nixon, K.L. Lobb, N.R. Mason, P.W. Stengel, S.L. Cockerham, S.A. Silbaugh, D.R. Gehlert, D.A. Schober, S. Iyengar, D.O. Calligaro, D. Regoli and P.A. Hipskind, 1995, Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist, J. Pharmacol. Exp. Ther. 275, 737.
11. Giuliani, S., C.A. Maggi, D. Regoli, G. Drapeau, P. Rovero and A. Meli, 1988, NK-1 receptors mediate the tachykinin stimulation of salivary secretion: selective agonists provide further evidence, Eur. J. Pharmacol. 150, 377.
12. Hancock, J.C. and G.W. Lindsay, 1995, Pressor and tachycardic responses to intravenous substance P in anesthetized rats, Peptides 16, 1439.
13. Helke, C.J., J.E. Krause, P.W. Mantyh, R. Couture and M.J. Bannon, 1990, Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors and regulatory mechanisms, FASEB J. 4, 1606.
14. Hipskind, P.A., J.J. Howbert, S. Cho, J.S. Cronin, S.L. Fort, F.O. Ginah, G.J. Hansen, B.E. Huff, K.L. Lobb, M.J. Martinelli, A.R. Murray, J.A. Nixon, M.A. Staszack and J.D. Copp, 1995, Practical and enantiospecific synthesis of LY303870, a novel NK-1 antagonist, J. Org. Chem. 60, 7033.
15. Hipskind, P.A., J.J. Howbert, R.F. Bruns, S.S.Y. Cho, T.A. Crowell, M.M. Foreman, D.R. Gehlert, S. Iyengar, K.W. Johnson, J.H. Krushinski, D.L. Li, K.L. Lobb, N.R. Mason, B.S. Muehl, J.A. Nixon, L.A. Phebus, D. Regoli, R.M. Simmons, P.G. Threlkeld, D.C. Waters and B.D. Gitter, 1996, 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists, J. Med. Chem. 39, 736.
16. Iyengar, S., P.A. Hipskind, D.R. Gehlert, D. Schober, B.D. Gitter, C. Mcmillian, R. Couture, D. Li and R.M.A. Simmons, 1995, LY303870: a centrally active NK-1 antagonist with a long duration of action, in: International Symposium: Tachykinins '95 - From Basic Science to Clinical Applications, Florence (Italy), October 16-18, Abstract, p. 122.
17. 1 receptors, Neuropharmacology 205, 167.
18. Lee, C.M., N.J. Campbell, B.J. Williams and L.L. Iversen, 1986, Multiple tachykinin binding sites in peripheral tissues and in brain, Eur. J. Pharmacol. 130, 209.
19. Lembeck, F., J. Donnerer, M. Tsuchiya and A. Nagahisa, 1992, The non-peptide tachykinin antagonist, CP-96,345, is a potent inhibitor of neurogenic inflammation, Br. J. Pharmacol. 105, 527.
20. Maggi, C.A., S. Giuliani, P. Santicioli, D. Regoli and A. Meli, 1987, Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors, J. Auton. Pharmacol. 7, 11.
21. Maggi, C.A., R. Patacchini, P. Rovero and A. Giachetti, 1993, Tachykinin receptors and tachykinin receptor antagonists, J. Auton. Pharmacol. 13, 23.
22. McLean, S., A. Fossa, S. Zorn and T. Rosen, 1995, Characterization of the interaction of the novel antagonist CP-122-721 with the NK-1 tachykinin receptor, in: International Symposium: Tachykinins '95 -From Basic Science to Clinical Applications, Florence (Italy), October 16-18, Abstract, p. 19.
23. Otsuka, M. and K. Yoshioka, 1993, Neurotransmitter functions of mammalian tachykinins, Physiol. Rev. 73, 229.
24. Pernow, B., 1983, Substance P, Pharmacol. Rev. 35, 85.
25. Persson, M.G., P. Hedqvist and L.E. Gustafsson, 1991, Nerve-induced tachykinin-mediated vasodilatation in skeletal muscle is dependent on nitric oxide formation, Eur. J. Pharmacol. 205, 295.
26. Pompei, P., S.J. Tayebati, C. Polidori, M. Perfumi, G. De Caro and M. Massi, 1993, Hypotensive effect of intravenous injection of tachykinins in conscious, freely moving spontaneously hypertensive and Wistar Kyoto rats, Peptides 14, 97.
27. Regoli, D., G. Drapeau, S. Dion and R. Couture, 1988, New selective agonists for neurokinin receptors: pharmacological tools for receptor characterization, Trends Pharmacol. Sci. 9, 920.
28. Rouissi, N., A. Claing, M. Nicolau, D. Jukic, P. D'Orleans-Juste and D. Regoli, 1993, Substance P (NK-1 receptor) antagonists: in vivo and in vitro activities in rats and guinea pigs, Life Sci. 52, 1141.
29. 1 receptor antagonist, in: International Symposium: Tachykinins '95 - From Basic Science to Clinical Applications, Florence (Italy), October 16-18, Abstract, p. 126.
30. 9]SP-like and septide-like peptides trigger different pharmacological responses in CHO cells transfected with human NK-1 receptor, in: International Symposium: Tachykinins '95 - From Basic Science to Clinical Applications, Florence (Italy), October 16-18, Abstract, p. 15.
31. 1) receptor, Science 251, 435.
32. Takeda, Y. and J.E. Krause, 1989a, Neuropeptide K potently stimulates salivary gland secretion and potentiates substance P-induced salivation, Proc. Natl. Acad. Sci. USA 86, 392.
33. Takeda, Y. and J.E. Krause, 1989b, γ-Preprotachykinin-(72-92)-peptide amide potentiates substance P-induced salivation, Eur. J. Pharmacol. 161, 267.
34. Whittle, B.J.R., J. Lopez-Belmonte and D.D. Rees, 1989, Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation, Br. J. Pharmacol. 98, 646.